Skip to content

Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage

Feasibility Study of Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03637283
Enrollment
100
Registered
2018-08-17
Start date
2018-10-01
Completion date
2021-12-01
Last updated
2018-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anti-VEGF, Branch Retinal Vein Occlusion, Vitrectomy

Brief summary

To evaluate the efficacy and safety of Anti-VEGF instead of intraoperative fan-shaped photocoagulation in BRVO combined with vitreous hemorrhage.

Interventions

PROCEDUREanti-VEGF

vitreoretinal surgery combined with intraoperative anti-VEGF

PROCEDUREfan-shaped photocoagulation

vitreoretinal surgery combined with intraoperative fan-shaped photocoagulation

Sponsors

Wenzhou Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Age ≥ 18 years old; 2. BRVO is diagnosed 3. Vitreous hemorrhage 4. Vitreous hemorrhage combined with mild retinal fibrovascular proliferation (early fibrous vascular membrane, thin fibrous vascular membrane, loose retinal adhesion and intact local retinal structure)

Exclusion criteria

1. BRVO combined with severe retinal fibrovascular proliferation (long-term fibrovascular membrane, thick fibrous vascular membrane and tightly attached to the retina, deformation of local retinal, retinal tear or suspension of retinal vein ) 2. BRVO combined with retinal detachment 3. Retinal veins are completely whitened 4. iris neovascularization or neovascular glaucoma 5. Combined glaucoma 6. combined with other retinopathy 7. Received anti-VEGF treatment within 3 months before surgery

Design outcomes

Primary

MeasureTime frameDescription
Mean change from baseline in best-corrected visual acuity (BCVA)3 yearsAssessed using the ETDRS protocol

Secondary

MeasureTime frameDescription
Mean change from baseline in visual field3 yearsAssessed on Humphery(30-2 and 60-4)
chang from baseline in structure of retina3 yearsAssessed on Optical Coherence Tomography(OCT)
chang from baseline in retinal neovascularization3 yearsAssessed on Fundus Fluorescein Angiography(FFA)

Contacts

Primary ContactYong Wei, M.D
weiyongdoctor@163.com+86 15057551266
Backup ContactWei Lin, M.D
linweiysg@163.com+86 13587560390

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026